SANTA FE, NM / ACCESSWIRE / February 26, 2020 / Sigma Labs, Inc. (NASDAQ:SGLB) ("Sigma Labs"), a leading developer of quality assurance software for the commercial 3D printing industry, has been awarded a contract by the Mississippi State University Center for Advanced Vehicular Systems (CAVS), a world-class interdisciplinary research center that uses state-of-the-art technology to address engineering challenges facing U.S. mobility industries.

The Mississippi State University Center for Advanced Vehicular Systems will install PrinteRite3D on a Renishaw AM400 machine, a new OEM platform for Sigma Labs, further proving out PrintRite3D's platform interoperability potential to an increasingly large machine base. Per the terms of the agreement, in addition to any research or commercial applications of PrintRite3D®, CAVS has agreed to serve as a real-world test bed for new product improvements that Sigma will roll out over time.

"The Research & Development and University sectors of the additive manufacturing (AM) market is important to Sigma as we expand our footprint in the retail market segment with another contract win with the Mississippi State University Center for Advanced Vehicular Systems, a leading research institution and thought leader," said Mark K. Ruport, Executive Chairman of Sigma Labs. "They have agreed to act as a test bed for new product improvements to PrintRite3D®, uniquely allowing us a real-world feedback loop to continuously improve our technology suite. I look forward to working with the entire team at CAVS to bring a new level of quality assurance to both their partners and the additive manufacturing industry as a whole," concluded Ruport.

PrintRite3D® is Sigma Labs' patented in-process quality assurance software for the commercial 3D metal printing industry, providing real-time melt pool analytics. The software uniquely leverages thermal signatures to monitor the quality of each product part in the production process, layer by layer and in real-time, allowing operators to correct or stop production of a defective part – resulting in reduced error rates and higher yields. The software is currently being evaluated by tier-1 aerospace and OEM partners worldwide.

About Mississippi State University Center for Advanced Vehicular Systems

The Center for Advanced Vehicular Systems (CAVS) is one of the premier university automotive research centers in the world, composed of over 300 staff and researchers in addressing some of today's most pressing challenges. CAVS is a strong partner at the state, national, and international level; with academic partnerships in place across multiple continents, CAVS forms collaborations which help us work smarter, faster, and more efficiently. Together with government and industry partners, CAVS is developing solutions to enhance transportation safety, improve vehicle efficiency, increase workforce productivity and enable a brighter future.

About Sigma Labs

Sigma Labs, Inc. (NASDAQ:SGLB) is a leading provider of quality assurance software to the commercial 3D printing industry under the PrintRite3D® brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time computer aided inspection (CAI) solutions known as PrintRite3D® for 3D advanced manufacturing technologies. Sigma Labs' advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance mid-production, uniquely allowing errors to be corrected in real-time. For more information, please visit www.sigmalabsinc.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could" are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K (including but not limited to the discussion under "Risk Factors" therein) filed with the SEC on April 1, 2019 and which may be viewed at www.sec.gov.

Contacts:

Media Contact:

Julia Wakefield
Vice President
Rubenstein Public Relations
212-805-3021
jwakefield@rubensteinpr.com
www.rubensteinpr.com

Investor Contact:

Chris Tyson
Managing Director
MZ Group – MZ North America
949-491-8235
SGLB@mzgroup.us
www.mzgroup.us

SOURCE: Sigma Labs, Inc.

ReleaseID: 577934

Ari Rabban joins executive panel, "How to Get in Early on the CPaaS Opportunity"

Newark, NJ / ACCESSWIRE / February 26, 2020 / Phone.com today announced that CEO and Co-Founder, Ari Rabban, has accepted an invitation to speak at the Channel Partners Conference and Expo 2020, being held March 9 – 12, 2020, at The Venetian and Sands Expo in Las Vegas, NV.

Rabban, a tenured enterprise communications leader of more than 20 years, will share his expertise and insights during the presentation, "How to Get In Early on the CPaaS Opportunity," moderated by analyst Jon Arnold.

Session attendees can expect to hear about the characteristics to look for in a successful CPaaS partner, how to overcome common challenges of incorporating CPaaS into a solutions portfolio, and how Phone.com's channel partner community benefits from its award-winning platform.

WHAT: How to Get in Early on the CPaaS Opportunity

WHO: Phone.com CEO and Co-Founder, Ari Rabban

WHEN: Wednesday, March 11, at 10:25 am

WHERE: Sands Expo, Level 2, Titian 2306

The Venetian and Sands Expo

Channel Partners Conference & EXPO

Phone.com combines carrier-grade telephony, omnichannel unified communications and collaboration services (UCaaS) with award-winning customer service and the industry's most flexible pricing. For channel partners, resellers and managed service providers, Phone.com offers scalable, reliable communications technology to support a diverse workforce comprised of mobile, remote and in-house employees.

"The ubiquity of cloud communications has opened the door for small businesses to access services that were once out of their reach," said Ari Rabban. "For channel partners, agents, resellers and solutions providers, this has created a much larger universe of potential customers.

"Today's market is fluid, and sustaining long-term growth requires solutions providers to stay current with advancements in technology, such as artificial intelligence and low-code APIs, as well as adapt to the needs of a multigenerational workforce. I am excited to connect with the many channel partners attending next month's conference and to sharing best practices for growing their business with CPaaS."

Ari Rabban is recognized as one of the earliest advocates for internet telephony and foremost experts in unified communications services. He is a regular contributor to Forbes and is frequently cited by industry analysts and media outlets worldwide.

About Informa Tech

Channel Futures, Channel Partners Online, Channel Partners Conference & Expo, Channel Partners Evolution and Channel Evolution Europe are part of Informa Tech, a market-leading B2B information provider with depth and specialization in the information and communications technology sector. We help drive the future by inspiring the technology community to design, build and run a better digital world through our market-leading research, media, training and event brands. Every year, we welcome 7,400+ subscribers to our research, more than 3.8 million unique monthly visitors to our digital communities, 18,200+ students to our training programs and 225,000 delegates to our events.

About Phone.com

Founded in 2008 by veteran telecommunication entrepreneurs, Phone.com provides more than 32,000 businesses across the U.S and Canada with comprehensive, flexible, and reliable cloud-based communication and collaboration solutions. Phone.com's innovative services, award-winning 24/7 U.S.-based support, coupled with experienced executive leadership and forward-thinking strategic planning, has led to 10 straight years of growth. With over 50 customizable features including audio and video conferencing, call forwarding, voicemail transcription, IVR, vanity and virtual toll-free 800 and local numbers, Phone.com's business VoIP allows you to connect with anyone anywhere at any time.

Phone.com has been recognized by the Inc. 500|5000 as well as Deloitte's Technology Fast 500 for fastest growing private companies. Connect with Phone.com on Facebook, follow us on Twitter, talk to us at 844-746-6312 or visit us at Phone.com

Contacts

 
Mostafa Razzak
 

JMRConnect
Work: 1-202-904-2048 Mobile: 1-917-912-0623

m.razzak@jmrconnect.net
 

Links

https://phone.com

SOURCE: Phone.com

ReleaseID: 577968

LOS ANGELES, CA / ACCESSWIRE / February 26, 2020 / StockNewsNow.com, The Official MicroCap News Source™, today published a SNNLive Video Interview with Diana Sabacinski, CEO of SanMelix Laboratories, Inc., a private company. SanMelix has created a product that aids in the healing of acute, chronic and minor wounds, according to the company's website (see here: www.startengine.com/sanmelix). The video interview was recorded at the MicroCap Rodeo 2019 in Austin, TX.

Click the following link to watch the SNNLive Video Interview:

SanMelix Laboratories, Inc. – Bioactive Wound Care Company Discusses BEECure™, Approval Process, IP Protection and Growth Drivers

You can follow Stock News Now on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE, and STOCKTWITS

Please review important disclosures on our website at http://stocknewsnow.com/legal.php#disclaimer

About SanMelix

Using the natural healing properties of Buckwheat honey, combined with our advanced bioactive enhancements, SanMelix has created a product that aids in the healing of acute, chronic and minor wounds. With IP protection on our BEECure™ M dressing and other pending patents, co-created by a renowned Harvard trained podiatric physician, SanMelix's advanced bioactive wound care products can be used in a host of settings and situations. We have created over-the-counter (OTC) skincare products such as ointments and creams designed to help in the healing of minor burns, scrapes, radiodermatitis and more. Our products will also be used for advanced wound care healing in hospitals and rehabilitation centers, by physicians through the use of dressings and ointments. For more information about SanMelix, please visit: www.startengine.com/sanmelix

About StockNewsNow.com

StockNewsNow.com is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. StockNewsNow.com is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature SNN-produced video like SNNLive CEO video interviews, as well as their latest news and headlines. Users can engage directly and share the information provided through social media.

Follow the companies YOU want to know more about; read and watch content from YOUR favorite microcap, emerging growth financial experts; register to attend financial conferences of YOUR choosing; find microcap and emerging growth financial professionals that YOU may be looking for – all here on StockNewsNow.com.

CONTACT:

StockNewsNow.com
info@snnwire.com

SOURCE: Stock News Now

ReleaseID: 577930

SEATTLE, WA / ACCESSWIRE / February 26, 2020 / Baristas Coffee Company, Inc. (OTCPK:BCCI) Baristas Coffee has begun a multi-tiered media marketing push specifically focused on Baristas White Coffee and overall market awareness.

This marketing push is a result of Baristas recently completing its largest production run with its co-packing supply partner along with smaller yet quicker production runs that have been completed utilizing Baristas in-house production line.

The advertising launch, which began today with digital exposure, is also planned to include television, radio, print, and new media. Initially, ads and promotions will direct consumers to www.trywhitecoffee.com or to purchase directly from Amazon at https://www.amazon.com/Baristas-Coffee-Single-Keurig-Compatible/dp/B01AO9JAHA/ref=sr_1_2?keywords=baristas+white+coffee&qid=1582641786&sr=8-2 and will leverage data from past media efforts to maximize the return from the exposure.

Barry Henthorn CEO stated: "We are confident that with our expanded allocation of production capabilities with our co-packer combined with our in-house production capabilities that we will be able to meet the inventory demands that are being driven by our latest marketing push. In the past, Baristas has been very successful in converting marketing into sales and has refined its messaging to create a low customer acquisition cost. Too often, this has translated into greater than expected orders with which we have struggled to maintain inventory. With both our largest production run to date now completed with our co-packing partner and our in house production capabilities, we believe that we will be able to quickly meet the demands created by our marketing push that began this morning."

Those who have followed the progress at Baristas are aware of the commitment Baristas has made in the past, creating a steady supply of news and information highlighting Baristas products, the progress the Company is making on increasing revenues, and expanding its' market share. The Company has also engaged in a renewed focus on informing investors of our weekly progress through media news coverage, financial insight messaging, expanded PR opportunities, creating awareness, and diversifying the Baristas investor and customer base.

The media buys, and other cutting edge marketing are made possible and were created via digital media frontrunner ReelTime Media (OTCPINK:RLTR) www.reeltime.com, whose capabilities are redefining how companies are evaluating and purchasing their TV, radio, print, and other new media. Baristas is now ready to support its new products and distributors with a marketing effort educating and driving consumers to consume Baristas' historical and new products.

About Baristas Coffee Company: Baristas is a national Coffee Company that is recognized throughout the US. It currently produces and sells coffee related products under the Baristas brand. The Baristas White Coffee single-serve cups compatible with the Keurig 2.0 brewing system is the bestselling product in its category. Baristas also market other coffee-related products. Baristas gained mainstream exposure when it became the subject of "Grounded in Seattle" the reality show special feature which aired on WE tv. It has been featured nationally including during Shark Tank on CNBC with Front Montgomery, CNN, ESPN, Food Network, Cosmopolitan Magazine, Forbes Magazine, Modern Living with Kathy Ireland, Sports Illustrated, NFL Monday and Thursday Night Football with Megs McLean, at NASCAR Races, at the 2019 Super Bowl, The Grammys, NBA TV, and other notable media.

CONTACT:
Barry Henthorn- CEO
barry@baristas.tv

SOURCE: Baristas Coffee Company Inc.

ReleaseID: 577893

LGBTQ100 ESG Index represents large-cap companies most dedicated to advancing equality

WEST HOLLYWOOD, CA / ACCESSWIRE / February 26, 2020 / LGBTQ Loyalty Holdings, Inc. (OTCPINK:LFAP), ("LGBTQ Loyalty" or "the Company"), a financial methodology and media company that quantifies corporate equality alignment with the LGBTQ community, announced today the full roster of corporations included in its LGBTQ100 ESG Index. This is the first public disclosure of the comprehensive listing, which comes as the Company introduces their LGBTQ100 Index Partnership Program.

"Our inaugural LGBTQ100 ESG Index is as historic as it is empowering, in that we have engaged the LGBTQ community to participate in our annual national survey with the large-cap businesses that represent our global financial Index," said Bobby Blair, CEO of LBGTQ Loyalty. "By announcing the 100 corporations included in the LGBTQ100 ESG Index, investors and consumers can embrace transparent insight into the corporations that implement diversity and inclusion best practices at the highest level, which are not only doing well, but are outperforming the marketplace."

Corporate constituents in the top selection of the LGBTQ100 ESG Index include: NortonLifeLock, Inc.; Amazon.com, Inc.; Apple, Inc.; Microsoft Corporation; Visa Inc. Class A; JP Morgan Chase & Co.; Mastercard Incorporated Class A; The Coca-Cola Company; Salesforce.com, Inc.; and Alphabet Inc. Class C. Click here for the comprehensive listing.

"This is a monumental Index milestone for the advancement of equality in Corporate America," said Kevin Hopper, Chief Product Officer at LGBTQ Loyalty. "The LGTBQ100 ESG Index is the first to incorporate direct input from the LGBTQ community into its Index methodology and constituent selection process, and we extend our congratulations to all of the companies included."

The LGBTQ100 ESG Index Partnership Program empowers Index constituents to share, educate and align with the pursuit of advancing equality across the business community from coast to coast. Leading the way with their diversity and inclusion initiatives, executives, managers and business owners can benefit and learn from these examples.

About the LGBTQ100 ESG Index

The LGBTQ100 ESG Index is comprised of 100 LGBTQ equality-driven companies from the nation's top 500 large-cap publicly traded companies. The LGBTQ100 ESG Index maintains industry sector grouping whereby each sector can represent up to 25% in the weighting calculation. The Index also screens for ESG and LGBTQ equality compliance, performance and alignment with the LGBTQ community through an annual corporate survey response from LGBTQ constituents across the country and is reconstituted annually. The Index is listed on the NYSE, ticker symbol: LGBTQ100. For more details and to monitor activity on the LGBTQ100 ESG Index, follow the hashtag #LGBTQ100 or visit www.LGBTQ100.com.

About LGBTQ Loyalty Holdings, Inc.

LGBTQ Loyalty is a financial methodology and media company that quantifies corporate equality alignment with the LGBTQ community and its supporters. The Company has benchmarked the first-ever U.S. Loyalty Preference Index, which the Company believes will empower the LGBTQ community to express their preferences for the nation's high-performing corporations most dedicated to advancing equality. Branded as LGBTQ100 ESG Index, it is an environmental, social and governance ("ESG") Index that offers an added perspective for those seeking to align with equality-driven, ESG-responsible corporations. LGBTQ Loyalty's leadership includes seasoned authorities in the financial industry and LGBTQ community.

Contact:
LGBTQ Loyalty Holdings, Inc.
750 N. San Vicente Boulevard
Suite 800 West
West Hollywood, CA 90069
press@lgbtqloyalty.com

LGBTQloyalty.com
1-310-870-9661

SOURCE: LGBTQ Loyalty Holdings, Inc.

ReleaseID: 577958

ORLANDO, FL / ACCESSWIRE / February 26, 2020 / LightPath Technologies, Inc. (NASDAQ:LPTH) ("LightPath," the "Company," or "we"), a leading vertically integrated global manufacturer, distributor and integrator of proprietary optical and infrared components and high-level assemblies, today announced that it has received a letter dated February 24, 2020 from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule").

The letter noted that (i) the Company's Class A common stock had a closing bid price of at least $1.00 for a minimum of ten consecutive trading days from February 7, 2020 to February 21, 2020, and (ii) the Company has regained compliance with the Bid Price Rule. Accordingly, Nasdaq considers the matter closed.

About LightPath Technologies

LightPath Technologies, Inc. (NASDAQ: LPTH) is a leading global, vertically integrated provider of optics, photonics and infrared solutions for the industrial, commercial, defense, telecommunications, and medical industries. LightPath designs, manufactures, and distributes proprietary optical and infrared components including molded glass aspheric lenses and assemblies, infrared lenses and thermal imaging assemblies, fused fiber collimators, and proprietary Black Diamond™ ("BD6") chalcogenide-based glass lenses. LightPath also offers custom optical assemblies, including full engineering design support. The Company is headquartered in Orlando, Florida, with manufacturing and sales offices in Latvia and China.

LightPath's wholly-owned subsidiary, ISP Optics Corporation, manufactures a full range of infrared products from high performance MWIR and LWIR lenses and lens assemblies. ISP's infrared lens assembly product line includes athermal lens systems used in cooled and un-cooled thermal imaging cameras. Manufacturing is performed in-house to provide precision optical components including spherical, aspherical and diffractive coated infrared lenses. ISP's optics processes allow it to manufacture its products from all important types of infrared materials and crystals. Manufacturing processes include CNC grinding and CNC polishing, diamond turning, continuous and conventional polishing, optical contacting and advanced coating technologies.

For more information on LightPath and its businesses, please visit www.lightpath.com.

Forward-Looking Statements

This news release includes statements that constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding our ability to expand our presence in certain markets, future sales growth, continued improvements in our financial results,and implementation of new distribution channels. This information may involve risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, factors detailed by LightPath Technologies, Inc. in its public filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. Except as required under the federal securities laws and the rules and regulations of the Securities and Exchange Commission, we do not have any intention or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Contacts:
Jim Gaynor, President & CEO
LightPath Technologies, Inc.
Tel: 407-382-4003
jgaynor@lightpath.com

Donald O. Retreage, Jr., CFO
LightPath Technologies, Inc.
Tel: 407-382-4003 x329
dretreage@lightpath.com

Jordan Darrow
Darrow Associates
Tel: 512-551-9296
jdarrow@darrowir.com

SOURCE: LightPath Technologies, Inc.

ReleaseID: 577909

Updated VenoValve data will include 8 Patients at 180 days – including 1 Patient at 365 Days Post VenoValve Surgery

IRVINE, CA / ACCESSWIRE / February 26, 2020 / Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on Wednesday, March 4, 2020, Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's first-in-man VenoValve study in Colombia, will present updated VenoValve data at the Thirty Second Annual Meeting of the American Venous Forum. The meeting is taking place March 3 to March 6 at the Omni Amelia Island Plantation Hotel at Amelia Island, Florida.

Contemporaneously with Dr. Ulloa's presentation at the American Venous Forum meeting, HJLI will release select VenoValve data from the presentation, which will include updated reports from 8 patients that are 180 days post VenoValve surgery (including 1 Patient that is now 365 days post VenoValve surgery).

The VenoValve is currently undergoing a first-in-man study in Colombia and was developed to treat chronic venous insufficiency ("CVI") due to valvular incompetence of the deep vein system. CVI is a condition that occurs when the valves in the veins of the leg are injured or destroyed, causing blood to flow backwards. The backwards flow of blood is known as reflux, and leads to the pooling of blood in the lower leg and increased venous pressure (venous hypertension) in the veins of the leg.

Endpoints for the VenoValve first-in-man study include reflux, measured by doppler, a VCSS score used by the clinician to measure disease severity, a VAS score used by the patient to measure pain, and VEINES qol/sym used to measure quality of life.

HJLI will submit the data from its first-in-man Colombia study as part of its Investigational Device Exemption ("IDE") application to be submitted to the U.S. Food and Drug Administration ("FDA") in order to begin the U.S. pivotal trial for the VenoValve. HJLI expects to file the IDE application in Q3 of 2020.

Approximately 2.4 million people in the U.S. suffer from CVI due to reflux in the deep venous system. Patients with venous ulcers from CVI in the U.S. spend an average of approximately $30,000 per year on wound care. Estimates indicate that direct medical costs from CVI in the U.S. exceed $30 Billion per year. There are currently no FDA approved devices or effective treatments for deep venous CVI.

The American Venous Forum (AVF) is dedicated to improving the care of patients with venous and lymphatic disease. Founded in 1987, AVF fosters cutting edge research and clinical innovation and educates health care professionals, patients and policy makers about venous and lymphatic diseases.

AVF's leadership and membership are recognized internationally as thought leaders, expert investigators and clinicians in venous and lymphatic disease.

About Hancock Jaffe Laboratories, Inc.

Hancock Jaffe Laboratories (NASDAQ:HJLI) specializes in developing and manufacturing bioprosthetic (tissue based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. Hancock Jaffe currently has two lead product candidates: the VenoValve®, a porcine based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency; and the CoreoGraft®, a bovine tissue based off the shelf conduit intended to be used for coronary artery bypass surgery. Hancock Jaffe has a 20-year history of developing and producing FDA approved medical devices that sustain or support life. The current management team at Hancock Jaffe has been associated with over 80 FDA or CE marked medical devices. For more information, please visit HancockJaffe.com.

Cautionary Note on Forward-Looking Statements

This press release and any statements of stockholders, directors, employees, representatives and partners of Hancock Jaffe Laboratories, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results (including, without limitation, the performance of the new board members described herein) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

HJLI Press Contacts:
Amy Carmer
Tel: 949-261-2900
Email: ACarmer@HancockJaffe.com

SOURCE: Hancock Jaffe Laboratories, Inc.

ReleaseID: 577951

Highlights:

Drilling underway at Dixie Creek Target following up Spatiotemporal Geochemical Hydrocarbon ("SGH") survey results
Two separate targets near common boundary with Great Bear Resources
Both SGH anomalies are proximal to induced polarization chargeability anomalies

VANCOUVER, BC / ACCESSWIRE / February 26, 2020 / BTU METALS CORP. ("BTU" or the "Company") (BTU-TSX:V) is pleased to announce that drilling is currently underway at the Dixie Creek Target to test gold exploration targets identified by independent specialty laboratory, Activation Laboratories Ltd. ("ActLabs") and coincident with BTU's own geophysical work, including induced polarization ("IP") chargeability anomalies.

Results from the SGH soil sampling program have been received and indicate two high priority gold exploration targets on BTU's Dixie Creek Target area. The SGH anomalies coincide with geologic structures that are clearly seen in geophysical surveys (e.g. see SGH anomalies over 2nd Vertical Derivative Magnetics in Figure 1). ActLabs has rated the Dixie Creek targets at a 5.5 out of 6 on its scale of prospectivity. SGH is the same technique neighboring Great Bear Resources ("GBR") has reported to have used to identify some areas of gold mineralization along the LP structural trend (see BTU press release dated Aug. 1, 2019).

BTU CEO, Paul Wood stated, "We are extremely excited to test these new gold exploration targets at Dixie Creek as many indicators are now pointing us there. The independent SGH report conclusions are supported by our own IP and drill results in which we identified the mafic-felsic contact consistent with the LP trend, where GBR continues to explore to the southeast on either side of BTU's Dixie Creek targets."

TNT Update

The downhole electromagnetic program is currently underway to target high-grade massive sulphide lenses within the neighbourhood of the grid of drill holes completed thus far at TNT.

Drill holes 21 through 33 in the TNT area are complete. The earlier holes are being assayed at two labs and the latter holes are being logged and sampled. Drilling will recommence at TNT as assays are returned and results of the downhole EM program identify the most prospective areas to host potential economic massive sulphides associated with the target Volcanogenic Massive Sulphide ("VMS" ) system.

Bruce Durham, VP of Exploration, commented; "With seventeen holes completed in the TNT area we now know it extends for more than 2,200 metres. The target is up to 500 metres wide – holes drilled to date are providing us with geological data and are rather widely spaced so they can act as platforms for downhole EM surveying. The TNT target is extensive, and the downhole EM survey may serve as a fast-track vectoring method to discover significant lenses of massive sulphides."

Figure 1: SGH Gold Anomalies circled over the 2nd Vertical Derivative of the Magnetics

The technical contents of this release were approved by Mr. Bruce Durham, P. Geo., a qualified person as defined by National Instrument 43-101.

BTU Metals Corp. is a publicly traded junior, mining exploration company focused in the Red Lake district of Ontario, Canada. BTU currently holds or has under option approximately 200 sq. km of exploration properties continuous to Great Bear Resources ("GBR") in the Red Lake, Ontario area. BTU is actively exploring two key targets; the Dixie Creek prospect, a high-grade gold exploration target immediately south of GBR and the TNT prospect, a large potential-VMS system in the southern part of the properties. For more information please visit www.BTUMetals.com.

ON BEHALF OF THE BOARD
"Paul Wood"

Paul Wood, CEO, Director
pwood@btumetals.com

FOR FURTHER INFORMATION, PLEASE CONTACT:

Andreas Curkovic, Investor Relations

+1 416-577-9927

BTU Metals Corp.

Telephone: 1-604-683-3995

Toll Free: 1-888-945-4770

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING STATEMENTS: This news release contains forward-looking statements, which relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and using information currently available to the Company. Investors are cautioned that these forward-looking statements are neither promises nor guarantees, and they are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward -looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances. All forward-looking statements made in this press release are qualified by these cautionary statements and by those made in our filings with SEDAR in Canada (available at WWW.SEDAR.COM).

SOURCE: BTU Metals Corp.

ReleaseID: 577962

Web and Mobile Platform to Help Consumers Better Manage Money, Lifestyle 

SAN CLEMENTE, CA / ACCESSWIRE / February 26, 2020 / Concierge Technologies, Inc. (OTCQB:CNCG), a diversified global holding company, today announced the formation of Marygold & Co., a new operating subsidiary that offers individuals and their families a secure way to send, receive, spend and save through its mobile platform.

Coming soon on both the Apple Play and Google Play stores as a pre-launch, wait-list beta version, the Marygold & Co. debit card and mobile app provides an FDIC-insured, digital alternative to traditional banking, empowering clients to take control of their finances anytime, anywhere, with no minimums, no credit checks and the ability to pay anyone in the U.S. immediately with an email address or mobile phone number. Consumers may sign-up now at www.marygoldandco.com for the U.S. beta launch, expected in summer of 2020, when accounts will begin to issue.

"Marygold & Co. represents a new fintech offering, built to bring what we believe to be the best-of-class mobile banking, savings and payment tools together in one customizable app to help consumers meet their unique banking objectives," said Chad Butler, Marygold & Co. president, who has more than 20 years of financial services experience across various specialties, including bank cards, payment processing and program management.

"We are enabling people to better organize their financial lives with our fintech solution, which gives clients full autonomy over how, where and when they make financial transactions, and provides freedom, flexibility and peace of mind when sending or receiving funds. We believe that one of most distinguishing characteristics and client benefits is that unlike others, Marygold &. Co. pays interest on deposits, combining the best of all worlds in one easy to use mobile app and debit card," Butler added.

Challenger banks such as Revolut, Monzo and N26 have become the standard in European countries. Across the United States, challenger banks such as Chime and Simple are springing up as banking deposit and spending alternatives, while others like Acorns and Robinhood focus on more savings and investment support. Additionally, payment platforms, including Venmo, Paypal and Zelle, have also become everyday means to send money via their specific channels.

"Today's news builds upon Concierge Technologies' roadmap to expand its financial services business, led by USCF Investments, our company's largest holding," said Nicholas Gerber, chairman and CEO, Concierge Technologies. "We are very excited at the opportunity of expanding into fintech, as the market potential for safe and secure mobile banking continues to grow among consumers."

Marygold & Co. is now accepting wait-list applicants for its zero-fee debit card and connected customizable savings accounts called Money Pools. High APY% is paid on all deposits to connected spending and savings accounts with no minimum balance requirements. The card is available for use anywhere Mastercard is accepted worldwide and can be used at nationwide network of no fee ATM's.

Marygold & Co is offering a free debit and associated savings account with no monthly maintenance fee, a $0 minimum balance requirement to open the account, and is FDIC-insured up to the maximum allowed. Minimum amount to open account is $0.00. Annual Percentage Yield (APY) accurate as of February 7, 2020 is 0.875% of debit spending accounts and 1.40% of money pool savings accounts. Rate is annual and monthly payments will be prorated based on number days in the month. Rate applies to balances of $0.01 or more. Rates may change after account is opened. Fees may reduce earnings.

Among other notable Marygold & Co. benefits are the ability:

to receive paychecks up to two days early by setting up direct deposit;
to instantly send money to anyone in the U.S. with a mobile phone number or email address; recipients can choose how they wish to receive funds, regardless of their bank, with real-time direct to debit deposit options;
to create customized, high APY%-earning money pool savings accounts with automated funding and goal mapping to support saving for life's notable events, such as a wedding or house down payment, or daily activities;
to split payments to two people, as well as to activate the platform's location-based security feature to block any transactions made in a different area from the cardholder's current position;
to turn off swipe payments, set up custom restrictions and instantly freeze and unfreeze accounts within the app if a card is lost or stolen.

The Marygold & Co. app will introduce native tap-and-pay capability for Android phones, as well as compatibility with Apple Pay, Google Pay and Samsung Pay, allowing consumers to seamlessly make purchases with their mobile phones that are secured with a 256-bit encryption, and providing optimal protection of personal and financial data. Future releases will support group and social events, including fund raisers, gifts and charity contributions.

Marygold & Co. bank accounts and debit cards are provided by Radius Bank, (pursuant to license from Mastercard International), with deposits insured up to the allowable limit.

About Marygold & Co.

Launching in 2020, Marygold & Co. is bringing private banking solutions previously limited to the wealthy directly into the hands of everyday consumers, with no credit-checks and no minimum balances. Learn more about the company's Mastercard debit card and fintech app solution by visiting www.marygoldandco.com.

About Concierge Technologies

Concierge Technologies is a diversified global holding firm with operating subsidiaries in financial services, beauty products, food manufacturing and security systems. Offices and manufacturing operations are in the U.S., New Zealand and Canada. For more information, visit

www.conciergetechnology.net.

Forward-Looking Statements

This press release may contain "forward-looking statements" that include information relating to Concierge Technologies' and its subsidiaries' future events and future financial and operating performance. Such forward-looking statements, including, but not limited to, the timing of the launch of Marygold & Co., should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

For a more detailed description of the risk factors and uncertainties affecting Concierge Technologies or its subsidiary companies, and more detailed information about the individual operating entities, please refer to the Company's Securities and Exchange Commission filings, which are available on the Company's website, (http://www.conciergetechnology.net), or at www.sec.gov.

Media and investors, for more Information, contact

Roger S. Pondel
PondelWilkinson Inc.
310-279-5980
rpondel@pondel.com

SOURCE: Concierge Technologies, Inc.

ReleaseID: 577882

– Dr. MacMichael brings over 35 years of experience in development and manufacture of therapeutic proteins, vaccines, and cell and gene therapies –
– Dr. MacMichael to play key role in guiding cell therapy CMC to advance XCART™ Platform –

FRAMINGHAM, MA / ACCESSWIRE / February 26, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today it has bolstered its product development expertise with the appointment of Greg MacMichael, Ph.D. to its Scientific Advisory Board ("SAB").

"We are pleased to welcome Dr. MacMichael to our SAB and to have the opportunity to leverage his extensive cell therapy CMC expertise as we work to develop the XCART™ platform. He has established a proven track record in the successful planning and execution of drug development and production over the course of his career and is a key addition to our team," commented Jeffrey Eisenberg, Chief Executive Officer of Xenetic. "As we execute on our preclinical development strategy, it is important that we pay close attention to manufacturing processes, which is particularly critical for complex cell therapy products, and an area of expertise Dr. MacMichael has developed over the course of his career. I believe the leadership and expertise that Dr. MacMichael brings will be integral in how we shape and advance the development program of XCART™ moving forward."

Since 2010, Greg MacMichael, Ph.D., has served as the President and Founder of CMC BioServices, LLC, a well-established consulting firm through which he has assisted innovators and biopharmaceutical companies with successful development and licensure of cell and gene therapies, biologics and vaccines. Dr. MacMichael most recently served as the Senior Vice President of Technical Operations at Axovant Gene Therapies where he oversaw the manufacturing of Axovant's pipeline of gene therapies. Over the course of his 35 years of experience in biopharmaceuticals, Dr. MacMichael held positions such as Senior Vice President of Development, Manufacturing and Quality Control at NantKwest Therapeutics and Senior Vice President of Process, Development, Manufacturing and Quality Assurance at Rocket Pharma. Additionally, he previously served as the Global Head of Biologics Process Development at Novartis, where he led the CMC aspects of Novartis' acquisition and transfer of Kymriah® from the University of Pennsylvania, including building the supply chain for plasmids, lentiviral vector and production capacity.

"I am pleased to be working alongside the Xenetic team at this transformational stage for the Company. The data generated to date by XCART™ is encouraging and I believe that this differentiated CAR T technology has the potential to address the need for a personalized approach to treating B-cell lymphomas," commented Dr. MacMichael. "I have spent my career in pharmaceutical manufacturing and product development and look forward to playing a critical role in maximizing the potential of the XCART™ platform."

Dr. MacMichael received his Ph.D. in microbiology/biochemistry from Mississippi State University, his M.S. in microbiology/biochemistry from North Carolina State University and his B.S. in microbiology from Pennsylvania State University.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Additionally, Xenetic is leveraging PolyXen®, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen® has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and receives royalty payments under this agreement.

For more information, please visit the Company's website at www.xeneticbio.com and connect on Twitter, LinkedIn, and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including, but not limited to, statements regarding the Company's plans to initially apply the XCART technology to advance cell-based therapeutics by targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas, and the Company's expectations that XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from the acquisition of the CAR T technology; (2) uncertainty of the expected financial performance of the Company following completion of the acquisition of the CAR T technology; (3) failure to realize the anticipated potential of the XCART technology; (4) the ability of the Company to implement its business strategy; and (5) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, periodic current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.

Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
xbio@jtcir.com

SOURCE: Xenetic Biosciences, Inc.

ReleaseID: 577868